Rabies virus inactivated antigen, A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rabies virus inactivated antigen, A
Accession Number
DB10283
Type
Biotech
Groups
Approved
Description
Not Available
Protein structure
No structure small
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Rabies virus strain flury lep antigen (propiolactone inactivated)
  • Rabies virus vaccine flury-lep strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RabAvertKitGlaxo Smith Kline Biologicals Sa2016-12-19Not applicableUs
RabAvertKitA S Medication Solutions2014-07-082017-06-20Us
RabAvertKitGsk Vaccines Gmb H2014-07-082020-03-31Us
Categories
UNII
FK894Q51YE
CAS number
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rabies virus inactivated antigen, A.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rabies virus inactivated antigen, A.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Rabies virus inactivated antigen, A.Experimental
2-MethoxyethanolThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with 2-Methoxyethanol.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Rabies virus inactivated antigen, A.Experimental, Illicit
AbataceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abatacept.Approved
AbciximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abciximab.Approved
abetimusThe risk or severity of adverse effects can be increased when abetimus is combined with Rabies virus inactivated antigen, A.Investigational
abetimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with abetimus.Investigational
AbituzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Rabies virus inactivated antigen, A.Investigational
ActeosideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Acteoside.Investigational
AdalimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adalimumab.Approved
AdecatumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with Rabies virus inactivated antigen, A.Investigational
AdefovirThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adefovir.Investigational
AducanumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Afelimomab.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rabies virus inactivated antigen, A.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rabies virus inactivated antigen, A.Experimental
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Rabies virus inactivated antigen, A.Approved, Withdrawn
AlefaceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept.Approved, Withdrawn
AlemtuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab.Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Rabies virus inactivated antigen, A.Investigational
AlicaforsenThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alicaforsen.Investigational
AlirocumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Rabies virus inactivated antigen, A.Approved
AltretamineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Altretamine.Approved
ALX-0081The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with ALX-0081.Investigational
AmatuximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rabies virus inactivated antigen, A.Approved
AMG 108The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Rabies virus inactivated antigen, A.Approved
AmsacrineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Amsacrine.Approved
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Rabies virus inactivated antigen, A.Approved
AnakinraThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rabies virus inactivated antigen, A.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Rabies virus inactivated antigen, A.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rabies virus inactivated antigen, A.Investigational
AnifrolumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).Approved
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).Approved
apolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Rabies virus inactivated antigen, A.Approved, Investigational
ApremilastThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Apremilast.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Rabies virus inactivated antigen, A.Investigational
AtezolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Atezolizumab.Approved
AVE9633The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Avelumab.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
AzacitidineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Rabies virus inactivated antigen, A.Approved
AzathioprineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Azathioprine.Approved
BapineuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Basiliximab.Approved, Investigational
BavituximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rabies virus inactivated antigen, A.Approved, Investigational
BectumomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Rabies virus inactivated antigen, A.Experimental
BegelomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Begelomab.Experimental
BelataceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Belatacept.Approved
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Rabies virus inactivated antigen, A.Approved
BelimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Belimumab.Approved
BenralizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Benralizumab.Investigational
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with Rabies virus inactivated antigen, A.Approved
BenznidazoleThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Benznidazole.Approved
BetamethasoneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bimagrumab.Investigational
bivatuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Rabies virus inactivated antigen, A.Approved
BleomycinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bleomycin.Approved
BlinatumomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Blinatumomab.Approved
BlosozumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brentuximab vedotin.Approved
BriakinumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Briakinumab.Investigational
BrodalumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brodalumab.Approved, Investigational
BudesonideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Budesonide.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Rabies virus inactivated antigen, A.Approved, Investigational
BusulfanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Busulfan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rabies virus inactivated antigen, A.Approved
CabazitaxelThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cabazitaxel.Approved
CanakinumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Canakinumab.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
CapecitabineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Capecitabine.Approved, Investigational
Capromab pendetideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Capromab pendetide.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Rabies virus inactivated antigen, A.Approved
CarboplatinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Carboplatin.Approved
CarlumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Carlumab.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Rabies virus inactivated antigen, A.Approved
CarmustineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Carmustine.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rabies virus inactivated antigen, A.Experimental
CastanospermineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Castanospermine.Experimental
CatumaxomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Catumaxomab.Investigational
Certolizumab pegolThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Certolizumab pegol.Approved
CetuximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Rabies virus inactivated antigen, A.Approved
ChlorambucilThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Chlorambucil.Approved
ChloroquineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Chloroquine.Approved, Vet Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rabies virus inactivated antigen, A.Approved
CisplatinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cisplatin.Approved
CixutumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
CladribineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cladribine.Approved, Investigational
ClazakizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Clazakizumab.Investigational
clenoliximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Rabies virus inactivated antigen, A.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rabies virus inactivated antigen, A.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rabies virus inactivated antigen, A.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rabies virus inactivated antigen, A.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
ClofarabineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Clofarabine.Approved, Investigational
ConatumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Rabies virus inactivated antigen, A.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rabies virus inactivated antigen, A.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Rabies virus inactivated antigen, A.Approved, Vet Approved
CorticotropinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cortisone acetate.Approved
CR002The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with CR002.Investigational
CR011-vcMMAEThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with CR011-vcMMAE.Investigational
CrenezumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
CyclophosphamideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rabies virus inactivated antigen, A.Approved, Investigational, Vet Approved
CyclosporineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Cytomegalovirus immunoglobulinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cytomegalovirus immunoglobulin.Experimental
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
DacarbazineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dacarbazine.Approved, Investigational
DacetuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daclizumab.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Rabies virus inactivated antigen, A.Approved
DactinomycinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dactinomycin.Approved
DalotuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
DasatinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Rabies virus inactivated antigen, A.Approved
DaunorubicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daunorubicin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rabies virus inactivated antigen, A.Approved
DeflazacortThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Deflazacort.Approved
DemcizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Rabies virus inactivated antigen, A.Investigational
DeoxyspergualinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Deoxyspergualin.Investigational
DepatuxizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Depatuxizumab.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rabies virus inactivated antigen, A.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Rabies virus inactivated antigen, A.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rabies virus inactivated antigen, A.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Rabies virus inactivated antigen, A.Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rabies virus inactivated antigen, A.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rabies virus inactivated antigen, A.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rabies virus inactivated antigen, A.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Dimethyl fumarateThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dimethyl fumarate.Approved, Investigational
DinutuximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dinutuximab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rabies virus inactivated antigen, A.Approved, Investigational
DocetaxelThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Docetaxel.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rabies virus inactivated antigen, A.Investigational
DoxifluridineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Doxifluridine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
DoxorubicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Doxorubicin.Approved, Investigational
DulaglutideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dulaglutide.Approved
DuligotuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Durvalumab.Approved
DusigitumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Eculizumab.Approved, Investigational
EdrecolomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Edrecolomab.Experimental
EfalizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Efalizumab.Approved, Investigational
ElotuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Emibetuzumab.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Rabies virus inactivated antigen, A.Approved
EpirubicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Epirubicin.Approved
EpratuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Rabies virus inactivated antigen, A.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Rabies virus inactivated antigen, A.Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Rabies virus inactivated antigen, A.Approved
EstramustineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Estramustine.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Rabies virus inactivated antigen, A.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rabies virus inactivated antigen, A.Approved
EtanerceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etanercept.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etaracizumab.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Rabies virus inactivated antigen, A.Approved
EtoposideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etoposide.Approved
EtrolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Rabies virus inactivated antigen, A.Approved
EverolimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Everolimus.Approved
EvolocumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Rabies virus inactivated antigen, A.Approved, Investigational
FingolimodThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fingolimod.Approved, Investigational
FirategrastThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Rabies virus inactivated antigen, A.Approved
FloxuridineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Rabies virus inactivated antigen, A.Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Rabies virus inactivated antigen, A.Approved
FludarabineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fludarabine.Approved
FludrocortisoneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fludrocortisone.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rabies virus inactivated antigen, A.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rabies virus inactivated antigen, A.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Rabies virus inactivated antigen, A.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rabies virus inactivated antigen, A.Approved
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Rabies virus inactivated antigen, A.Approved
FluorouracilThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Rabies virus inactivated antigen, A.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Rabies virus inactivated antigen, A.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rabies virus inactivated antigen, A.Approved
FontolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Rabies virus inactivated antigen, A.Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Gallium nitrateThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gallium nitrate.Approved, Investigational
GanitumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Rabies virus inactivated antigen, A.Approved
GemcitabineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gemtuzumab ozogamicin.Approved
GevokizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Glatiramer AcetateThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Glatiramer Acetate.Approved, Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with Rabies virus inactivated antigen, A.Approved
GlimepirideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Glimepiride.Approved
GolimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Golimumab.Approved
GS 0573The risk or severity of adverse effects can be increased when GS 0573 is combined with Rabies virus inactivated antigen, A.Investigational
GS 0573The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with GS 0573.Investigational
GuselkumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Guselkumab.Approved
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Rabies virus inactivated antigen, A.Investigational
GusperimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gusperimus.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Rabies virus inactivated antigen, A.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Rabies virus inactivated antigen, A.Approved
Human C1-esterase inhibitorThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Human C1-esterase inhibitor.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Rabies virus inactivated antigen, A.Approved
HydroxyureaThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Rabies virus inactivated antigen, A.Investigational
HypericinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hypericin.Investigational
IbalizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibalizumab.Investigational
Ibritumomab tiuxetanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rabies virus inactivated antigen, A.Approved
IbrutinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibrutinib.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Rabies virus inactivated antigen, A.Approved
IcatibantThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Icatibant.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Rabies virus inactivated antigen, A.Approved
IdarubicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Idarubicin.Approved
IdarucizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Rabies virus inactivated antigen, A.Approved
IdelalisibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Rabies virus inactivated antigen, A.Approved
IfosfamideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ifosfamide.Approved
IGN311The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Rabies virus inactivated antigen, A.Approved
ImatinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Imatinib.Approved
IMC-1C11The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Rabies virus inactivated antigen, A.Approved, Investigational
ImiquimodThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Imiquimod.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Infliximab.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Inotuzumab ozogamicin.Approved
IntetumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ipilimumab.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Rabies virus inactivated antigen, A.Approved, Investigational
IrinotecanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Irinotecan.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rabies virus inactivated antigen, A.Investigational
IxekizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Rabies virus inactivated antigen, A.Approved, Nutraceutical
L-PhenylalanineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with L-Phenylalanine.Approved, Nutraceutical
LabetuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
LeflunomideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Rabies virus inactivated antigen, A.Approved
LenalidomideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lenalidomide.Approved
lerdelimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rabies virus inactivated antigen, A.Investigational
LisofyllineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lisofylline.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Rabies virus inactivated antigen, A.Approved
LomustineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lomustine.Approved
Lorvotuzumab mertansineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LumiliximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mavrilimumab.Investigational
MDX-1100The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with MDX-1100.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Rabies virus inactivated antigen, A.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Rabies virus inactivated antigen, A.Approved
MechlorethamineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mechlorethamine.Approved
MEDI-528The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with MEDI-528.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Rabies virus inactivated antigen, A.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Rabies virus inactivated antigen, A.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Rabies virus inactivated antigen, A.Approved
MelphalanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Melphalan.Approved
MepolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mepolizumab.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Rabies virus inactivated antigen, A.Approved
MercaptopurineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mercaptopurine.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Rabies virus inactivated antigen, A.Approved
MethotrexateThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Methotrexate.Approved
MethylprednisoloneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Rabies virus inactivated antigen, A.Approved
MitomycinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mitomycin.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Rabies virus inactivated antigen, A.Approved, Investigational
MitoxantroneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rabies virus inactivated antigen, A.Investigational
MizoribineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mizoribine.Investigational
MogamulizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mogamulizumab.Investigational
MORAb-009The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with MORAb-009.Investigational
motavizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with motavizumab.Investigational
MuromonabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Muromonab.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rabies virus inactivated antigen, A.Approved
Mycophenolic acidThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mycophenolic acid.Approved
MYO-029The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rabies virus inactivated antigen, A.Approved, Investigational
NafamostatThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nafamostat.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Rabies virus inactivated antigen, A.Investigational
NebacumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Necitumumab.Approved
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
NelarabineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nelarabine.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
NilotinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nilotinib.Approved, Investigational
nimotuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Obinutuzumab.Approved
OcrelizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ocrelizumab.Approved, Investigational
OfatumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Olaratumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rabies virus inactivated antigen, A.Investigational
OlokizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Olokizumab.Investigational
OmalizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
OxaliplatinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Oxaliplatin.Approved, Investigational
OzanezumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rabies virus inactivated antigen, A.Approved, Vet Approved
PaclitaxelThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Rabies virus inactivated antigen, A.Approved
PalbociclibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Palbociclib.Approved
PalivizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Rabies virus inactivated antigen, A.Approved, Investigational
PanobinostatThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Panobinostat.Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Paquinimod is combined with Rabies virus inactivated antigen, A.Investigational
PaquinimodThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Paquinimod.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rabies virus inactivated antigen, A.Approved
PatritumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rabies virus inactivated antigen, A.Approved
PazopanibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pazopanib.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Rabies virus inactivated antigen, A.Approved, Investigational
PegaspargaseThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pegaspargase.Approved, Investigational
PembrolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Rabies virus inactivated antigen, A.Approved, Investigational
PemetrexedThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pemetrexed.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
PentostatinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pentostatin.Approved, Investigational
PertuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rabies virus inactivated antigen, A.Approved, Investigational
PimecrolimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Rabies virus inactivated antigen, A.Investigational
PirarubicinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rabies virus inactivated antigen, A.Investigational
PirfenidoneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pirfenidone.Investigational
Polatuzumab VedotinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rabies virus inactivated antigen, A.Approved
PomalidomideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pomalidomide.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Rabies virus inactivated antigen, A.Approved
PralatrexateThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pralatrexate.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Rabies virus inactivated antigen, A.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rabies virus inactivated antigen, A.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rabies virus inactivated antigen, A.Approved
PrednisoloneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rabies virus inactivated antigen, A.Experimental
PRO 140The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rabies virus inactivated antigen, A.Approved
ProcarbazineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Procarbazine.Approved
R1507The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Raxibacumab.Approved
reslizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with reslizumab.Investigational
RI 624The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Rabies virus inactivated antigen, A.Approved
RilonaceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rilonacept.Approved
RilotumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Rabies virus inactivated antigen, A.Approved
RituximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rituximab.Approved
RobatumumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rabies virus inactivated antigen, A.Approved
RuxolitinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ruxolitinib.Approved
Sacituzumab govitecanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sacituzumab govitecan.Investigational
SAR3419The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with SAR3419.Investigational
SarilumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sarilumab.Approved
SecukinumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Secukinumab.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Rabies virus inactivated antigen, A.Investigational
SemapimodThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Semapimod.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Rabies virus inactivated antigen, A.Experimental
SeocalcitolThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Seocalcitol.Experimental
SeribantumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Seribantumab.Investigational
SGN-40The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with SGN-40.Investigational
SibrotuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Siltuximab.Approved
siplizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rabies virus inactivated antigen, A.Approved, Investigational
SirolimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sirolimus.Approved, Investigational
SirukumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
SorafenibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sorafenib.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Rabies virus inactivated antigen, A.Approved
SteproninThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Stepronin.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Rabies virus inactivated antigen, A.Approved
StreptozocinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Streptozocin.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
SunitinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sunitinib.Approved, Investigational
SYM001The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Rabies virus inactivated antigen, A.Approved, Investigational
TacrolimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tacrolimus.Approved, Investigational
TanezumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
TemozolomideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rabies virus inactivated antigen, A.Approved
TemsirolimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Rabies virus inactivated antigen, A.Approved
TeniposideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Teniposide.Approved
TeplizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Rabies virus inactivated antigen, A.Vet Approved
TepoxalinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Rabies virus inactivated antigen, A.Approved
TeriflunomideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Teriflunomide.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tetanus Immune Globulin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Rabies virus inactivated antigen, A.Approved, Investigational, Withdrawn
ThalidomideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Rabies virus inactivated antigen, A.Approved
ThiotepaThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Thiotepa.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Rabies virus inactivated antigen, A.Approved
TioguanineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tioguanine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Rabies virus inactivated antigen, A.Approved
TNX-901The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
TofacitinibThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tofacitinib.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Rabies virus inactivated antigen, A.Approved, Investigational
TopotecanThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Topotecan.Approved, Investigational
TositumomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tositumomab.Approved
TovetumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
TrabectedinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trabectedin.Approved, Investigational
TralokinumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trastuzumab emtansine.Approved
TRC105The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Rabies virus inactivated antigen, A.Approved, Investigational, Nutraceutical
TretinoinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Rabies virus inactivated antigen, A.Investigational
TriptolideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Rabies virus inactivated antigen, A.Investigational
TrofosfamideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trofosfamide.Investigational
UstekinumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ustekinumab.Approved, Investigational
VedolizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vedolizumab.Approved
VeltuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Rabies virus inactivated antigen, A.Approved
VilanterolThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vilanterol.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Rabies virus inactivated antigen, A.Approved
VinblastineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
VincristineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Rabies virus inactivated antigen, A.Approved
VindesineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vindesine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
VinorelbineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vinorelbine.Approved, Investigational
VisilizumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Rabies virus inactivated antigen, A.Investigational
VoclosporinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Voclosporin.Investigational
volociximabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with volociximab.Investigational
XmAb 2513The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with XTL-001.Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Not Available
ATC Codes
J06AA06 — Rabies serum
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPlasmodium Falciparum Malaria1
1CompletedPreventionPlasmodium Falciparum Malaria / Plasmodium Infections1
1Unknown StatusPreventionPlasmodium Infections1
1, 2CompletedPreventionPlasmodium Infections1
2CompletedPreventionPlasmodium Falciparum Malaria1
2CompletedPreventionPlasmodium Infections2
2CompletedPreventionRabies1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingPreventionPlasmodium Infections1
2Unknown StatusPreventionRabies Pre-exposure Prophylaxis1
3CompletedPreventionEncephalitis, Japanese B / Meningococcal Disease / Meningococcal Meningitis / Rabies / Salmonella Typhi Infection / Yellow Fever1
3CompletedPreventionRabies Infection1
3CompletedPreventionRabies Post-exposure Prophylaxis1
3CompletedPreventionRabies Prevention1
4CompletedNot AvailableRabies1
4CompletedPreventionRabies1
4CompletedPreventionRabies Vaccine Allergy1
4RecruitingPreventionRabies1
Not AvailableCompletedPreventionRabies Exposure / Rabies Prevention1
Not AvailableNot Yet RecruitingNot AvailablePlasmodium Infections1
Not AvailableRecruitingPreventionRabies1
Not AvailableRecruitingTreatmentRabies1
Not AvailableUnknown StatusNot AvailableDog Bite1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 30, 2015 14:24 / Updated on September 14, 2017 11:25